Cargando…
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
Temozolomide (TMZ) is an important first-line treatment for glioblastoma (GBM), but there are limitations to TMZ response in terms of durability and dependence on the promoter methylation status of the DNA repair gene O(6)-methylguanine DNA methyltransferase (MGMT). MGMT-promoter-hypermethylated (MG...
Autores principales: | Wu, Qiong, Berglund, Anders E., Macaulay, Robert J., Etame, Arnold B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606804/ https://www.ncbi.nlm.nih.gov/pubmed/37894860 http://dx.doi.org/10.3390/ijms242015179 |
Ejemplares similares
-
Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma
por: Wu, Qiong, et al.
Publicado: (2019) -
The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma
por: Wu, Qiong, et al.
Publicado: (2021) -
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010) -
Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023) -
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)